News / American Regent
Shirley, NY–August 26, 2023: American Regent, Inc., a Daiichi Sankyo Group company, today announced results from the phase 3 HEART-FID trial of INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency in adult heart failure patients with reduced ejection fraction (HFrEF).
Basking Ridge, NJ and Shirley, NY – June 5, 2023: Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) approved INJECTAFER® (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure categorized as New York Heart Association class II/III to improve exercise capacity.
Melville, NY – May 2, 2023: American Regent® is pleased to announce the launch of Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)
Melville, NY – March 23, 2023: American Regent announces the launch of sulfite-free Epinephrine Injection, USP.
Melville, NY – May 2, 2023: American Regent® is pleased to announce the launch of Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)
Shirley, NY – American Regent, Inc., a U.S. manufacturer of pharmaceuticals for human and veterinary use with manufacturing sites in New York and Ohio, today announced it acquired HBT Labs, Inc. based in California.
Melville, NY – August 9, 2022: American Regent, Inc. has announced the launch of Atropine Sulfate Injection, USP, a longstanding injectable medication, now with FDA approval.
Melville, NY – March 31, 2022: American Regent, Inc. is pleased to announce the launch of Selenious Acid Injection, USP in a new concentration and vial size.
Melville, NY – June 28, 2022: American Regent, Inc. and Provepharm Life Solutions are pleased to announce the availability of ProvayBlue® (methylene blue) Injection, USP in a 10 mL single-dose vial.
Melville, NY – February 3, 2022: American Regent announces the introduction and availability of FDA-approved Vasopressin Injection, USP. Vasopressin is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
For patients as young as one year of age who have intolerance to, or have had an unsatisfactory response to, oral iron, Injectafer may now be administered for IDA treatment1
Basking Ridge, N.J. and Shirley, N.Y. (December 15, 2021) – Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved Injectafer for pediatric patients (who are 1 year of age or older) with iron deficiency anemia (IDA) who are intolerant to oral iron or who have had an unsatisfactory response to oral iron.
Melville, NY – September 2, 2021: American Regent, Inc. introduces FDA-approved Multrys™ (trace elements injection 4*, USP). Multrys™ is indicated in neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Melville, NY – July 1, 2020: – American Regent announces the introduction and availability of HydrALAZINE Hydrochloride Injection, USP—“AP” Rated and therapeutically equivalent to Apresoline® 1,2.
Basking Ridge, N.J. and Shirley, N.Y. (May 6, 2021): Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved a single 1000 mg dose option of Injectafer® (ferric carboxymaltose injection), an iron replacement product, for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron, have had unsatisfactory response to oral iron, or have non-dialysis dependent chronic kidney disease (CKD).1
Shirley, NY – April 1, 2021: Paul Diolosa assumed the role of President and CEO of American Regent, Inc., a Daiichi Sankyo Group company, effective today.
Melville, NY – September 30, 2020: American Regent, Inc. announces the introduction of Tralement® (trace elements injection 4*, USP), the first and only FDA-approved multi-trace element injection.
Melville, NY – September 30, 2020: American Regent, Inc. announces the introduction of Tralement® (trace elements injection 4*, USP), the first and only FDA-approved multi-trace element injection.
Shirley, NY – May 7, 2020: American Regent announced the introduction of the only FDA approved USP standard Nicardipine Hydrochloride Injection.
Shirley, NY – American Regent announces the introduction and availability of Estradiol Valerate Injection, USP
Shirley, NY – American Regent, Inc. announced the introduction of FDA approved Zinc Sulfate Injection, USP.
Shirley, NY – American Regent, Inc. announced the introduction of FDA approved Zinc Sulfate Injection, USP.
Shirley, NY - American Regent today announced the introduction of Selenious Acid Injection, USP.
Shirley, NY - American Regent today announced the re-introduction of Aminocaproic Acid Injection, USP.
Melville, NY – September 14, 2023:
Learn more about the St. John’s University and American Regent Post-Doctoral Pharmaceutical Industry Fellowship by downloading our brochure. Information on how to apply to our program as well as key deadlines are included.
Shirley, NY - American Regent, Inc. today announced the re-introduction of Droperidol Injection, USP.
Luitpold Pharmaceuticals, Inc., a manufacturer and distributor of pharmaceuticals that addresses diverse medical and veterinary needs, announced it changed its legal name to American Regent, Inc. effective January 2, 2019.
Shirley, NY — American Regent today announced the launch and availability of Fomepizole Injection, AP rated and therapeutically equivalent to Antizol®.